CAS NO: | 2756809-34-2 |
包装 | 价格(元) |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
生物活性 | HDAC-IN-30 is a novel multi-targetHDACinhibitor, includingHDAC1(IC50=13.4 nM),HDAC2(IC50=28.0 nM),HDAC3(IC50=9.18 nM),HDAC6(IC50=42.7 nM),HDAC8(IC50=131 nM). HDAC-IN-30 exhibits potent antitumor efficacy[1]. | ||||||||||||||||||||||||
IC50& Target |
| ||||||||||||||||||||||||
体外研究 (In Vitro) | HDAC-IN-30 (compound 8 h; 0.5, 1, 2 μM; 48 hours) can effectively activate the p53 pathway by promoting the phosphorylation of p53[1]. HDAC-IN-30 (0, 1, 2.5, 5 mM; 48 hours; HepG2 cells) induces cell cycle arrest at the G2 phase in a concentration-dependent manner[1]. HDAC-IN-30 (0, 1, 2.5, 5 mM; 48 hours) possesses prominent anticancer activity in HepG2 cells[1]. Western Blot Analysis[1]
Cell Cycle Analysis[1]
Apoptosis Analysis[1]
| ||||||||||||||||||||||||
体内研究 (In Vivo) | HDAC-IN-30 (12, 24 mg/kg; intraperitoneal injection, every two days for 4 weeks) exhibits potent anticancer activity and no side effects even at high dose (24 mg/kg)[1].
| ||||||||||||||||||||||||
分子量 | 405.45 | ||||||||||||||||||||||||
Formula | C22H23N5O3 | ||||||||||||||||||||||||
CAS 号 | 2756809-34-2 | ||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |